Is GHRP-6 approved or legal?

No. GHRP-6 is not approved as a therapeutic drug in any major jurisdiction, and it is prohibited in sport by WADA (category S2). Products sold online are for research use only, not for human consumption. Legality of possession varies by jurisdiction.

How is GHRP-6 dosed and what is its half-life?

There is no validated clinical dose. Human pharmacology studies used weight-based IV doses (100-400 mcg/kg); anecdotal community protocols cite roughly 100-300 mcg subcutaneously 2-3 times daily, often with a GHRH analog. The active window is very short (distribution half-life around 7-8 minutes; effects roughly 15-30 minutes), with the GH pulse peaking within about 15-30 minutes. This is reference information, not dosing advice.

How is GHRP-6 different from GHRP-2?

Both are ghrelin-receptor agonists that release GH, but GHRP-6 is notably stronger at stimulating hunger and appetite, which is its signature effect. GHRP-2 has more human data (including a diagnostic approval in Japan) and a somewhat different cortisol/prolactin profile. Neither is an approved therapy.

Does GHRP-6 actually do anything?

Its GH-releasing and appetite-stimulating effects are well documented in humans, and animal studies show cardioprotective effects. But there are no large controlled human trials proving therapeutic benefit for recovery, body composition, or heart health, so durable clinical benefit is unproven.

Short-term human studies suggest reasonable tolerability, with the main effects being strong hunger and transient rises in cortisol and prolactin. Long-term safety is unstudied, chronic GH-axis stimulation carries the same theoretical concerns as GH itself, and unregulated product quality is a real risk. It is not approved for human use.

Hormonal

GHRP-6

Also known as: Growth Hormone Releasing Peptide-6, GHRP6, SKF-110679, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

The prototypical growth-hormone-releasing peptide and ghrelin-receptor agonist, best known for strongly stimulating both GH release and appetite; characterized human...

Last updated July 11, 2026

Buy GHRP-6

Overview

GHRP-6 is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and the prototypical growth-hormone-releasing peptide. It was among the earliest GH secretagogues discovered (by Cyril Bowers and colleagues) and acts as an agonist at the growth-hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the natural hormone ghrelin. Like ghrelin, it prompts the pituitary to release growth hormone in pulses while also strongly stimulating appetite - the feature most consistently reported with GHRP-6, generally more pronounced than with GHRP-2. The published evidence is concentrated in pharmacology rather than clinical outcomes. Human studies have characterized GHRP-6's pharmacokinetics and its dose-dependent capacity to release GH and increase food intake, while a substantial body of preclinical work in rodent and large-animal models reports cytoprotective and cardioprotective effects. There are no large controlled clinical efficacy trials and no regulatory approval of GHRP-6 as a therapeutic in any major jurisdiction. It is worth noting a common point of confusion: the [D-Lys3] analog of GHRP-6 is, by contrast, a widely used ghrelin-receptor antagonist in laboratory research and should not be conflated with GHRP-6 itself. GHRP-6 is prohibited in sport by WADA, and material sold online is labeled for research use only. This entry summarizes the published science and community-reported practice for reference only. It is not medical advice and does not endorse human use.

How it works

GHRP-6 binds GHS-R1a, a Gq-coupled G-protein-coupled receptor in the pituitary and hypothalamus. Receptor activation drives the phospholipase-C / IP3 / diacylglycerol pathway, mobilizing intracellular calcium and triggering pulsatile GH release from somatotrophs. It also acts at the hypothalamus to promote GHRH release and to blunt somatostatin tone, so its GH effect synergizes with GHRH and GHRH analogs. The same GHS-R1a signaling that drives GH release also stimulates appetite and food intake, which is why hunger is GHRP-6's signature effect. In animal models GHRP-6 additionally shows cytoprotective and cardioprotective actions (reduced infarct size, lower oxidative stress, pro-survival signaling) that appear at least partly independent of GH release; these cardioprotective findings remain preclinical.

Researched effects

Clinical Stimulates pulsatile growth-hormone release from the pituitary in humans
Clinical Strongly increases appetite and food intake via ghrelin-receptor (GHS-R1a) activation
Clinical Synergizes with GHRH and GHRH analogs to amplify GH release
Preclinical Reduces oxidative injury and myocardial necrosis in animal models of heart attack and drug-induced cardiotoxicity
Preclinical Cytoprotective and pro-survival effects across multiple tissues in animal models
Anecdotal Improved recovery, sleep, appetite for bulking, and body composition with regular use

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No approved or established therapeutic dosing in humans. Published human pharmacology used weight-based dosing: a formal pharmacokinetic study administered single intravenous boluses of 100, 200, and 400 mcg/kg, and earlier dose-response work showed GH release in roughly the 1 mcg/kg range intravenously. These studies establish acute GH-releasing capacity and tolerability, not a validated treatment regimen.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Community guides and forum discussion commonly describe reconstituted subcutaneous doses of roughly 100-300 mcg, taken 2-3 times daily, frequently stacked with a GHRH analog (such as CJC-1295, sermorelin, or Mod GRF 1-29) to produce synergistic GH pulses; around 100 mcg is often cited as near the per-injection saturation point. Users consistently report strong, rapid-onset hunger as the hallmark effect. These figures reflect unverified community practice rather than tested safe or effective doses.

Half-life: Very short. A human pharmacokinetic study reported a rapid distribution half-life of about 7-8 minutes; the functionally relevant window is commonly summarized as roughly 15-30 minutes, with the GH pulse peaking around 15-30 minutes after injection. (The same study also detected a longer terminal elimination phase of a few hours, but the biologically active window is brief.)
Routes: subcutaneous, intramuscular, intravenous

Safety & side effects

GHRP-6's most distinctive effect is a marked increase in hunger and appetite, stronger than with other GHRPs. Other reported effects include transient, dose-dependent rises in cortisol and prolactin, injection-site reactions, water retention, transient changes in blood sugar, and occasional tingling/numbness. GH secretagogues as a class are described as generally well tolerated over the short term with few serious adverse events, but long-term human safety - including any effect on cancer risk - is unstudied, and chronic stimulation of the GH/IGF-1 axis carries the same theoretical concerns as growth hormone itself. Product quality is a real-world risk because research-grade material is unregulated and may be impure or mislabeled. GHRP-6 is not approved as a therapeutic drug, and it is prohibited in sport by WADA (category S2). This information is for research reference only and is not a recommendation for human use.

Research summary

GHRP-6's core pharmacology is well established in humans: it reliably releases growth hormone, increases food intake via the ghrelin receptor, and synergizes with GHRH, and its pharmacokinetics (a very short active window) have been formally characterized. Its appetite-stimulating effect is the most consistent and clinically tangible action. Beyond that pharmacology, the evidence base is dominated by preclinical work. A series of animal studies report cardioprotective and cytoprotective effects - reduced infarct size and oxidative stress in myocardial-infarction models and protection against drug-induced cardiotoxicity - but these have not been confirmed in controlled human trials, and there is no approved therapeutic indication. GHRP-6 has less human data than its sibling GHRP-2. The honest assessment is that GHRP-6 is a well-understood GH secretagogue and potent appetite stimulant with intriguing preclinical cardioprotective signals, but unproven human therapeutic benefit and no long-term safety data. It should be treated as a research compound rather than a validated treatment.

FAQ

Is GHRP-6 approved or legal?: No. GHRP-6 is not approved as a therapeutic drug in any major jurisdiction, and it is prohibited in sport by WADA (category S2). Products sold online are for research use only, not for human consumption. Legality of possession varies by jurisdiction.
How is GHRP-6 dosed and what is its half-life?: There is no validated clinical dose. Human pharmacology studies used weight-based IV doses (100-400 mcg/kg); anecdotal community protocols cite roughly 100-300 mcg subcutaneously 2-3 times daily, often with a GHRH analog. The active window is very short (distribution half-life around 7-8 minutes; effects roughly 15-30 minutes), with the GH pulse peaking within about 15-30 minutes. This is reference information, not dosing advice.
How is GHRP-6 different from GHRP-2?: Both are ghrelin-receptor agonists that release GH, but GHRP-6 is notably stronger at stimulating hunger and appetite, which is its signature effect. GHRP-2 has more human data (including a diagnostic approval in Japan) and a somewhat different cortisol/prolactin profile. Neither is an approved therapy.
Does GHRP-6 actually do anything?: Its GH-releasing and appetite-stimulating effects are well documented in humans, and animal studies show cardioprotective effects. But there are no large controlled human trials proving therapeutic benefit for recovery, body composition, or heart health, so durable clinical benefit is unproven.
Is GHRP-6 safe?: Short-term human studies suggest reasonable tolerability, with the main effects being strong hunger and transient rises in cortisol and prolactin. Long-term safety is unstudied, chronic GH-axis stimulation carries the same theoretical concerns as GH itself, and unregulated product quality is a real risk. It is not approved for human use.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.